Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.2115
Abstract: In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis was shown to be an effective treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Further assessment of the efficacy of tafamidis in patients with more… read more here.
Keywords: patients advanced; tafamidis patients; class iii; tafamidis ... See more keywords